The acquisition provides expanded technical services that will support the testing and training needs of pharmaceuticals manufacturers and retailers alike.

“In fulfilling one of our key strategic objectives, we are delighted to become part of NSF International, an organisation like ourselves, founded on and developed through sound ethical principles and core values,” says Bob Pietrowski, managing partner at DBA. “We are confident that this partnership will bring significant benefits to both parties, and we look forward to the prospect of bringing our unparalleled GMP and regulatory training and auditing expertise to a broader international client base.”

Expanding training services in Europe

Established in 1986, DBA has an international reputation in the field of pharmaceutical quality management, regulatory compliance and training. DBA’s leading position in the UK gives NSF an expanded presence in the European market, while providing additional training services to meet the unique needs of clients worldwide.

“This is an outstanding opportunity for both organisations to expand our global biotech services,” said Kevan P. Lawlor, CEO and president of NSF.

This acquisition will also complement other services provided by Global Lifescience Solutions, an NSF International company, that offers a wide array of services to the pharmaceutical, biotech, and dietary supplement industries, including:

• Analytical testing
• High-content screening
• Stability storage and testing
• Bioanalytical testing for clinical trials

While continuing DBA’s mission in providing high-quality, pharmaceutical services, NSF International plans to operate DBA as a standalone business within NSF UK Limited, LLC.